D-0914-2023 Class II Terminated
FDA drug recall D-0914-2023 was initiated by SUN PHARMACEUTICAL INDUSTRIES INC on Jul 10, 2023 and is designated Class II. Reason for recall: Failed Impurities: Out of Specification (OOS) result observed during Related Substances testing The recall status is terminated (terminated Dec 18, 2023). Affected quantity: 8,880 30-count bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Jul 19, 2023
- Initiation Date
- Jul 10, 2023
- Termination Date
- Dec 18, 2023
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 8,880 30-count bottles
Product description
Tiagabine Hydrochloride Tablets, 2 mg, 30-count bottle, Distributed by Sun Pharmaceutical Industries. Inc. Cranbury NJ 08512, Manufactured by: Sun Pharmaceutical Industries Limited Halol-Baroda Highway, Halol-389 350, Gujarat, India. NDC#: 62756-200-83
Reason for recall
Failed Impurities: Out of Specification (OOS) result observed during Related Substances testing
Distribution pattern
Distributed nationwide in the USA.
Code information
Lot HAC3339A, Expires 07/2023
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0914-2023
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026